We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Pfizer Acquires Minority Interest in AM-Pharma

News   May 12, 2015

 
Pfizer Acquires Minority Interest in AM-Pharma
 
 
 

RELATED ARTICLES

Discontinuing Oral Immunotherapy for Peanut Allergy Reduces Its Protective Effects

News

A study has followed participants after oral immunotherapy (OIT) for peanut allergy have found that discontinuing OIT or continuing OIT at a reduced dose led to a decline in its protective effects.

READ MORE

Some Cancer Drugs Don’t Work by Hitting Their Targets

News

Some cancer drug candidates in clinical trials kill cancerous cells through off-target effects instead of by interacting with their intended molecular targets, according to new study findings.

READ MORE

Drug That Combats Memory Loss in Alzheimer's Enters Phase II Trials

News

A new drug may protect against memory loss, nerve damage and other symptoms of Alzheimer's disease. The drug called BPN14770 is now in Phase 2 clinical trials in patients with Alzheimer's and Fragile X syndrome.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE